Tag Archive for: Collaboration

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center

/in

Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA. The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance […]

Read more

Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland

/in

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces it has entered into an exclusive licensing agreement with Cooper Consumer Health  (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise the […]

Read more

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

/in

Deal value includes upfront payment of US$100 million with F2G eligible for additional regulatory and commercial milestones of up to US$380 million, as well as double-digit royalties on net sales and share development costs Validation of Novo Holdings’ strategy to identify and invest in promising European biotech opportunities Novo Holdings A/S, a leading international life sciences […]

Read more

DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology

/in

Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Anticancer Bioscience Ltd., an innovative China-base and international company pioneers in synthetic lethal approaches to precision oncology, today announced a notable collaboration pertaining to the development of silica-based long-acting controlled release treatments in oncology. The collaboration joins […]

Read more

Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

/in

Shionogi to conduct clinical trials, subsequent registration, and commercialization of olorofim for invasive aspergillosis (IA) in Europe and Asia F2G to receive upfront payment of $100m and share development costs F2G will also be eligible for additional regulatory and commercial milestones of up to $380m, as well as double-digit royalties on net sales OSAKA, Japan, […]

Read more